Click to view this email in a browser
Forward this message to a colleague
Special Message From CAMA Co-Chairs
It’s finally here—2015—a date that is synonymous with the close of the Millennium Development Goals (MDGs) and the launch of the Sustainable Development Goals (SDGs). While the New Year brings an enthusiasm for fresh starts, it also signals the acceleration of work still to be completed in the fight against malaria. Within CAMA, we are indebted to you for your continued support of the Alliance both in dollars and in-kind resources.
In 2014, we carried out several activities and convenings, built relationships with new and valuable stakeholders, welcomed a new addition to the team and facilitated the start of our 2015 program planning process. All of which gives us the confidence to carry out a robust plan, with your partnership, in this very important milestone year. A snapshot of our key successes include:
We are proud of the progress we collectively made in 2014. With your continued partnership, guidance and support we look forward to achieving more in the year ahead. As usual, do not hesitate to reach any of us on the CAMA team by emailing firstname.lastname@example.org with your comments and questions. Together we can achieve a malaria free world!
Here’s wishing you a year filled with continued achievements and successful partnerships.
Tuesday, February 3 | 11:00 EST/4:00 PM UTC
In 2015 CAMA will host a series of quarterly calls to bring together members and key partners to discuss pertinent issues on malaria, share ongoing plans and opportunities for engagement and brainstorm ideas on malaria actions in the transition to the SDGs.
Please RSVP to email@example.com. Dial-in details and agenda will be circulated to confirmed participants.
Highlighted below are opportunities for CAMA members and others to become more engaged in the fight against malaria. Contact us for more information on these and other opportunities.
Does your company implement, fund or support a malaria program in Nigeria? Do you partner with a company on an innovative malaria program in Nigeria? If so, CAMA wants to know! In support of the NMEP’s push to gather more information on the private sector’s engagement in malaria, CAMA is facilitating a call for case studies to share knowledge and promote the private sector as an active partner in the malaria fight. Completed case studies will be disseminated across the GBCHealth, NMEP, Roll Back Malaria Partnership and broader malaria networks in 2015.
The Global Health Corps fellowship program is a unique opportunity for accomplished young professionals to develop the leadership skills and relationships that will prepare them for deepened impact on global health over the course of their careers.
Two Global Health Corps positions are currently available at GBCHealth; the Malaria Program Officer will promote business engagement on malaria, supporting the CAMA team. Applications close Feb. 3rd, 2015.
The Private Sector Delegation (PSD) to the Board of the Global Fund is now accepting applications for Board Member and Alternate Board Member positions for the upcoming 2015-2017 term. The PSD Board Member and Alternate will represent the private sector as a voting constituency to the Global Fund’s governance board for a two-year term starting on April 1st, at the close of the Global Fund 33rd Board Meeting. Board Representatives are elected by the PSD Advisory Group, a group of member companies committed to providing ongoing input and guidance on decisions and matters related to the Global Fund. Read more here.
Interested applicants must submit a candidate questionnaire to firstname.lastname@example.org no later than February 12th.
An innovative partnership is integrating nutrition provision into the delivery platform of malaria prevention to reduce child mortality during the rainy season.
Undernourishment is a significant underlying factor in the deaths of an estimated 1.5 million children in Africa each year, including about 50 percent of malaria associated deaths. Integrating nutrition programming with Seasonal Malaria Chemoprevention (SMC), campaigns has the potential to provide nutritional fortification to an additional 18.7 million children.
In Kano state, a four-month pilot launched by CHAI, UNICEF and the Government of Nigeria with funding from the Children’s Investment Fund and commodity donations by Nutriset, hopes to generate evidence on the impact of nutrition programs on malaria outcomes, and the operational feasibility of adding such interventions to SMC delivery.
It is anticipated that expanded integrated programs could be funded through leveraging existing and future funding for SMC delivery platforms—ten African countries have already adopted SMC delivery platforms, making the immediate scale-up of shared delivery of SMC and nutrition feasible.
Isaiah comes to GBCHealth with over six years of experience implementing development initiatives aimed at combating HIV/AIDS, malaria, and environmental degradation and incorporating business models for such interventions, Isaiah is the co-founder of HACEY Health Initiative and of the International Youth Alliance on Family Planning. A testament to his leadership, Isaiah has received countless recognitions for his work including the prestigious Queen Elizabeth Young Leaders Award.
Isaiah can be reached at email@example.com.
RESEARCH AND ADVOCACY
The World Malaria Report 2014 reveals that while we continue to make tremendous progress towards a malaria free world, we are still falling short:
In 2013, international and domestic funding for malaria control and elimination totaled USD 2.7 billion; although representing a threefold increase since 2005, this is still significantly below the estimated USD 5.1 billion required to achieve global targets for malaria control and elimination. International and domestic funders must prioritize further investments for malaria control.
Africa continues to carry the burden of the disease with 90 percent of deaths still occurring on the continent; Nigeria and DRC remain key epicenters of the disease.
Vector control interventions have increased significantly with over 200 million insecticide treated bednets produced in 2014 and can contribute to further reducing child deaths by the end of 2015. However, more needs to be done to foster new technologies in vector control, ensure quality control and get products approved and to market rapidly.
Resistance continues to play a major challenge to a malaria free world. The detection of P.falciparum resistance to artemisinin threatens to reverse the progress made in countries such as Myanmar, while pyrethroid resistance in Anopheles mosquito vectors in sub-Saharan Africa also poses a threat in a region where ITN intervention is the leading preventative measure.
Dr. Fatoumata Nafo-Traore (Executive Director, RBM Partnership) warns that efforts to contain Malaria may be jeopardized by the Ebola crisis.
In 2012, malaria killed 7,000 in Sierra Leone, Liberia and Guinea, and while these countries have since reached key malaria control targets, the necessary dedication of health resources to Ebola risks reversing malaria gains.
One key problem is that the early symptoms of Ebola and malaria are very similar. “According to Nafo, “at the moment when people have fevers, they are often afraid to go to healthcare facilities because they want to avoid being held in the Ebola treatment centers.” In Monrovia, Doctors Without Borders (MSF) is distributing antimalarial medicines to both prevent and treat new malaria cases and to minimize the number of people with malaria at Ebola treatment centers. Read Nafo’s full statement here.
Visit GBCHealth’s Ebola Outbreak Update page for more on the current epidemic, and contact us if you are interested in learning how your company can manage malaria in the face of the Ebola Outbreak.
By Leith Greenslade (Vice-Chair, Child Health, MDG Health Alliance)
We are in the midst of a maternal and child survival revolution. In the last 25 years, the number of children who die before turning five has halved—from over 12 million to just over 6 million—as has the number of women and girls dying of pregnancy related causes. For the first time in humanity’s history we can contemplate a world in which preventable maternal and child deaths are close to zero.
The fight against malaria has contributed significantly to the decline in child deaths. The World Malaria Report in 2013 found that between 2000 and 2010 three million fewer children died from malaria. Success in controlling malaria means that the problem is becoming more concentrated in specific countries. The vast majority of child malaria deaths now occur in a handful of countries in sub-Saharan Africa. Just two countries—Nigeria and the Democratic Republic of Congo—account for a massive 40 percent of the burden.
Integrating maternal and child health interventions with malaria interventions is imperative because increased coverage of high impact maternal and child survival interventions leads to dramatic results; using existing health outreach platforms that deliver interventions straight to the consumer increases the probablity that those in greatest need will receive care; it is cost-effective; and it delivers increased patient value.
Continue reading the full article here.
Launched in March 2014, the Global Fund’s new approach to grant-making offers recipient countries greater predictability and flexibility. During the 2014-2016 allocation period, the Global Fund will allocate USD 16.38 billion to the fight against the three diseases (read more about the allocations here).
So, how does the new funding model (NFM) impact funding for malaria? What types of funding can countries access for their malaria programs? What can RBM and the private sector do to ensure malaria is adequately funded?
Whitney White, Focal Point for the Private Sector Delegation to the Global Fund answers these questions and more here.
Only four classes of insecticide are currently recommended by the World Health Organization Pesticide Evaluation Scheme (WHOPES) for indoor residual spraying (IRS), with no new classes of insecticide for adult mosquito control having been introduced in the past forty years. With widespread and growing resistance to many of these compounds, malaria control programs have had very limited control options.
In a major development, Sumitomo Chemical has announced the recent submission to WHOPES of a new mode of action insecticide product for application in IRS programs. As this product has a different mode of action chemistry from currently available interventions, it is ideally suited for use in resistant management strategies and will help preserve the effectiveness of existing vector control tools. It is anticipated that this product will help combat the growing threat of insecticide resistance and will complement currently available vector control tools.
Read the full release here.
Leveraging core competencies and taking advantage of the collective impact of partnerships
ExxonMobil’s response began as a workplace program and has evolved into a fully integrated signature community investment initiative, helping to mitigate effects of malaria on their business while helping countries and communities to meet malaria control targets.
In addition to donating more than USD 120 million since 2000, ExxonMobil applies their business competencies to the fight against malaria, including in the areas of portfolio management, supply chain consulting on net distribution and providing governance and management assistance to NGOs.
Following a clear set of indicators and plan to reduce child mortality and improve maternal health in Nigeria, ExxonMobil has embarked on numerous partnerships including with the Family Care Association on the Nigeria Malaria Control and preventive program, NMCPP to provide free LLINs, training for health workers and free RDTs, targeting families, pregnant women and children under-5 in seven states. Together, ExxonMobil and partner programs have reached almost 105 million people, provided 13 million nets, 2 million treatments, 1.1 million RDTs and trained more than 335,000 health care workers.
First shipment marks a critical step in improving access to treatment worldwide
Sanofi and PATH announced the delivery of the first large-scale batches of antimalarial treatments manufactured with a new semisynthetic artemisinin derivative to malaria-endemic countries in Africa including the Democratic Republic of Congo, Liberia and Nigeria.
The supply of artemisinin, a key ingredient in artemisinin-based combination therapies (ACTs) derived from the sweet wormwood plant, is volatile due to a number of factors, leading to inconsistent price and periodic shortages. The commercial production of semisynthetic artemisinin will strengthen the artemisinin supply chain, stabilize pricing and ensure greater availability of treatment.
Steve Davis, President and CEO of PATH, stated, “Semisynthetic artemisinin demonstrates how public-private partnerships, tenacity and an urgent and shared goal—saving children’s lives—can drive promising innovations to transformative global scale.”
IN THIS ISSUE
UPCOMING MEETINGS AND EVENTS
March 31-April 1
World Malaria Day
Global Malaria Technical Strategy Launches at World Health Assembly
Q2 CAMA Members Teleconference
CAMA State Level Partnership Workshop
CAMA MEMBERS IN THE NEWS
ACCESS BANK PLC
MALARIA NEWS AND UPDATES
22 September 2014
To have the effectiveness of the MDGs in saving lives and controlling Malaria, UCSF Global Health Sciences argues for the need to make SDGl 3 specific and measurable.
The latest in RBM’s Progress & Impact Series notes the profound impact that malaria control interventions have had on maternal and newborn health—averting an estimated 94,000 newborn deaths.
Professor William Brieger, (JHPIEGO) provides details on how the private sector is truly starting to take on some of the burden of disease control.
WHAT TO WATCH
Switching Poles (Institute of Tropical Medicine in Antwerp)
Africa Cup of Nations (United Against Malaria)
Community Engagement is Key to Malaria Prevention (Africa AIRS)
Eradicating Malaria is Critical to Healthier, More Productive Future (Joy Phumaphi, ALMA)
Corporate Alliance on Malaria in Africa Members and Representatives
Chair: Ernesto De La Torre, Global Public Health Coordinator, Chevron
Current Alliance Members
The Corporate Alliance on Malaria in Africa (CAMA) is a unique coalition of companies from various industries, all with business interests in Africa. Launched by Marathon Oil in 2006 and with GBCHealth as implementing partner and Secretariat, CAMA brings the collective force and voice of the private sector to drive impact on malaria in Africa from control to elimination.
For more information on how your company or organization can get involved, please contact Isaiah Owolabi at firstname.lastname@example.org.